ATOS NASDAQ
Atossa Therapeutics, Inc.
1W: +23.2%
1M: -4.9%
3M: +2.6%
YTD: -75.3%
1Y: -83.0%
3Y: -79.7%
5Y: -95.4%
$2.34
+0.07 (+3.08%)
Weekly Expected Move ±12.2%
$2
$2
$2
$3
$3
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
0.00
Neutral
0 bullish
0 neutral
0 bearish
Articles (24h)
0
No articles in the last 24 hours
0.00
Neutral
0 bullish
1 neutral
0 bearish
Articles (7d)
1
Daily Sentiment (7 Days)
Articles (27)
Atossa plans CVR with $50 million cap
ATOS: Multiple Catalysts Converge in 2H26
Atos achieves CMMC 2.0 Level 2 certification, strengthening readiness for mission-critical and complex defense programs
ATOS: Raises up to $16.5 Million in Registered Direct Offering
Atossa Therapeutics Announces Closing of Registered Direct Offering of up to $16.5 Million in Gross Proceeds
12 Health Care Stocks Moving In Thursday's Intraday Session
Crude Oil Edges Higher; Driven Brands Posts Upbeat Earnings
12 Health Care Stocks Moving In Thursday's Pre-Market Session
ATOS: Initiating Coverage of Atossa Therapeutics; Endoxifen’s Expanding Opportunity from Oncology to Orphan Disease
Atossa Therapeutics GAAP EPS of -$1.11
Atossa Therapeutics Reports First Quarter 2026 Financial Results and Provides a Corporate Update
Atossa Therapeutics Reports First Quarter 2026 Financial Results and Provides a Corporate Update
[10-Q] ATOSSA THERAPEUTICS, INC. Quarterly Earnings Report - Stock Titan
Atos and CNA strengthen long-term strategic partnership through new multi-year infrastructure services agreement
Atossa Therapeutics Receives FDA Rare Pediatric Disease Designation for (Z)-Endoxifen for McCune-Albright Syndrome
Atos Advances AI-Ready Digital Transformation with Lumen Network as a Service
Atossa Therapeutics GAAP EPS of -$4.04 misses by $0.22
Atossa Therapeutics Reports Fourth Quarter and Year-End 2025 Financial Results and Provides a Corporate Update
Atossa Therapeutics Reports Fourth Quarter and Year-End 2025 Financial Results and Provides a Corporate Update
Atossa Genetics Inc. (NASDAQ:ATOS) Short Interest Up 29.7% in January
Atossa Therapeutics Issues Letter to Shareholders Highlighting 2025 Accomplishments and 2026 Outlook
Atossa Genetics (NASDAQ:ATOS) Shares Set to Reverse Split on Monday, February 2nd
Atossa Genetics Inc. (NASDAQ:ATOS) Receives $6.33 Consensus PT from Brokerages
Atossa Therapeutics' Founder and CEO Steven Quay, M.D., Ph.D. Named One of The Top 50 Healthcare Technology CEOs of 2025
Reviewing Atossa Genetics (NASDAQ:ATOS) and Autonomix Medical (NASDAQ:AMIX)
Atossa Genetics Inc. (NASDAQ:ATOS) Sees Large Increase in Short Interest
Atossa Genetics (NASDAQ:ATOS) Stock Crosses Below Two Hundred Day Moving Average – Here’s What Happened